RT Journal Article SR Electronic T1 Diuretic MAG3 Scintigraphy (F0) in Acute Pyelonephritis: Regional Parenchymal Dysfunction and Comparison with DMSA JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1955 OP 1963 VO 41 IS 12 A1 Sfakianakis, George N. A1 Cavagnaro, Felipe A1 Zilleruelo, Gaston A1 Abitbol, Carolyn A1 Montane, Brenda A1 Georgiou, Mike A1 Ezuddin, Shabbir A1 Mallin, William A1 Sfakianakis, Efrosyni A1 Strauss, Jose YR 2000 UL http://jnm.snmjournals.org/content/41/12/1955.abstract AB 99mTc-DMSA late static planar imaging or SPECT is being used for the investigation of focal acute pyelonephritis (APN), especially in children with urinary tract infection (UTI). Diuretic 99mTc-mercaptoacetyltriglycine (MAG3) dynamic scintirenography has been applied in the evaluation of kidney function and structure, frequently to exclude obstruction. However, in children and adults with a clinical picture of APN, diuretic MAG3 scintigraphy with zero time injection of furosemide (MAG3-F0) was observed to display focal parenchymal abnormalities; regional dysfunction (focal parenchymal decrease in early uptake; slow filling in and prolonged late retention of activity); or, less frequently, fixed defects. This observation was further studied both retrospectively and prospectively, and its sensitivity and specificity for APN were compared with those of dimercaptosuccinic acid (DMSA). Methods: In the retrospective study, for 36 children with UTI and regional parenchymal findings on MAG3-F0, data were reviewed, analyzed, and compared with the results of concurrent DMSA studies. In the prospective study, for 57 children with clinical and laboratory findings suggestive of APN, the 2 radiopharmaceuticals were used for imaging sequentially and the results of the 2 studies were compared. The criteria for abnormal findings compatible with the diagnosis of APN were, for MAG3-F0, regional parenchymal dysfunction and fixed focal defects and, for DMSA, focal defects without parenchymal loss. Results: In all groups of patients, most abnormal MAG3-F0 studies (80%) showed regional parenchymal dysfunction, but in some (20%) a fixed defect was found. Compared with DMSA and when both regional dysfunction and focal defects were considered, MAG3-F0 was as sensitive as DMSA. Some patients had only MAG3-F0 abnormalities, suggesting a slightly lower specificity for MAG3-F0 compared with DMSA (86%); this finding needs further study, because it also raises questions about the sensitivity of DMSA, considering that only a small percentage of patients with clinically suggestive findings had abnormal study findings. In most patients with fixed defects on both DMSA and MAG3-F0, follow-up studies showed no resolution, suggesting that a fixed defect on MAG3-F0 may indicate either more severe APN or preexistent scars and that regional dysfunction may be a sign more specific for APN and prognostic of potential recovery. In addition, a pattern more specific for a scar—a fixed defect with a dilated regional calyx—was seen on follow-up MAG3-F0. Conclusion: A fast (25-min) planar dynamic MAG3-F0 study was found to be as sensitive at depicting focal parenchymal abnormalities in APN as was the 3- to 4-h DMSA routine procedure. The sensitivity and specificity of both studies need further evaluation.